CA
NZ
UK
AU
IND
US
…
Valion Bio, Inc. operates as a late-stage biopharmaceutical company. Its lead drug candidate is Entolimod, a TLR5 agonist that is in late-stage development to treat acute radiation syndrome. The company's pipeline also comprises Entolimod to treat Neutropenia and lymphocyte exhaustion; and Entolasta, an immunologically optimized variant of Entolimod for chronic applications, such as immunosenescence. In addition, it offers CDMO services. The company was formerly known as Tivic Health Systems, Inc. and changed its name to Valion Bio, Inc. in April 2026. The company was incorporated in 2016 and is based in San Antonio, Texas.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
Valion Bio Inc (NASDAQ: VBIO) is a publicly listed biotechnology company. Long-term growth may depend on progression of any clinical programs, favorable regulatory outcomes, strategic partnerships and access to capital, which could make the stock attractive to investors seeking early-stage biotech exposure.
Primary risks include limited public disclosure about operations, high R&D and regulatory execution risk typical of early-stage biotechs, the likelihood of dilution from future financing and low trading liquidity that could amplify share volatility.
Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Income before tax | -7.99M | -4.47M | -8.24M | -10.10M | -8.49M |
| Net income | -8.88M | -5.66M | -8.24M | -10.10M | -8.49M |
| Selling general administrative | 4.77M | 3.16M | 4.75M | 5.88M | - |
| Selling and marketing expenses | 0.80M | 1.19M | 2.12M | 2.79M | - |
| Gross profit | 0.03M | -0.35M | 0.29M | 0.30M | -0.05M |
| Reconciled depreciation | 0.01M | 0.35M | 0.18M | 0.17M | - |
| Ebit | -7.85M | -4.42M | -8.24M | -10.10M | -5.63M |
| Ebitda | -7.84M | -4.06M | -8.06M | -9.92M | -5.61M |
| Depreciation and amortization | 0.01M | 0.35M | 0.18M | 0.17M | 0.02M |
| Operating income | -7.90M | -4.42M | -8.24M | -10.10M | -5.63M |
| Other operating expenses | 7.90M | 4.42M | 9.42M | 11.94M | 6.89M |
| Interest expense | 0.15M | 0.00M | - | - | 1.82M |
| Interest income | 0.02M | 0.01M | 0.00M | 0.00M | - |
| Net interest income | -0.12M | 0.01M | 0.00M | 0.00M | - |
| Total revenue | 0.38M | 0.00M | 1.18M | 1.84M | 1.26M |
| Total operating expenses | 7.90M | 4.06M | 8.53M | 10.40M | 5.59M |
| Cost of revenue | 0.35M | 0.35M | 0.89M | 1.54M | 1.30M |
| Total other income expense net | -0.10M | -0.05M | 0.00M | 0.00M | -2.86M |
| Net income from continuing ops | -7.99M | -4.47M | -8.24M | -10.10M | - |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Total assets | 31.61M | 2.81M | 5.16M | 5.88M | 15.04M |
| Intangible assets | 2.24M | - | - | - | - |
| Other current assets | 0.36M | 0.25M | 0.33M | 0.82M | 0.79M |
| Total liab | 14.81M | 0.27M | 1.58M | 2.25M | 1.76M |
| Total stockholder equity | 16.80M | 2.54M | 3.58M | 3.63M | 13.27M |
| Other current liab | 0.20M | 0.15M | 0.34M | 0.39M | 0.27M |
| Common stock | 0.00M | 0.00M | - | - | 0.00M |
| Capital stock | 0.00M | 0.00M | 0.00M | 0.00M | - |
| Retained earnings | -52.60M | -43.54M | -37.89M | -29.64M | -19.55M |
| Cash | 12.64M | 2.00M | 3.40M | 3.52M | 12.97M |
| Total current liabilities | 0.65M | 0.27M | 1.40M | 1.88M | 1.22M |
| Net debt | -6.19M | -2.00M | -3.03M | -2.99M | -12.27M |
| Short term debt | 0.50M | - | 0.19M | 0.16M | 0.16M |
| Short long term debt total | 6.45M | - | 0.37M | 0.53M | 0.71M |
| Other stockholder equity | 69.39M | 46.08M | 41.47M | 33.27M | 32.82M |
| Total current assets | 13.01M | 2.64M | 4.65M | 5.31M | 14.29M |
| Net receivables | 0.00M | 0.07M | 0.17M | 0.11M | 0.09M |
| Long term debt | 6.45M | - | - | - | - |
| Inventory | - | 0.32M | 0.76M | 0.86M | 0.43M |
| Accounts payable | 0.26M | 0.12M | 0.71M | 1.32M | 0.79M |
| Non currrent assets other | 0.26M | 0.17M | 0.03M | 0.03M | 0.05M |
| Non current assets total | 18.60M | 0.17M | 0.51M | 0.57M | 0.75M |
| Capital lease obligations | - | 0.00M | 0.37M | 0.53M | - |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Investments | -0.12M | 0.00M | - | - | - |
| Total cashflows from investing activities | -0.70M | - | -0.12M | -0.01M | - |
| Net borrowings | - | - | - | 0.00M | - |
| Total cash from financing activities | 18.35M | 4.33M | 8.51M | -0.53M | 17.54M |
| Net income | -7.99M | -4.47M | -8.24M | -10.10M | -8.49M |
| Change in cash | 10.64M | -1.39M | -0.12M | -9.46M | 11.93M |
| Begin period cash flow | 2.00M | 3.40M | 3.52M | 12.97M | 1.04M |
| End period cash flow | 12.64M | 2.00M | 3.40M | 3.52M | 12.97M |
| Total cash from operating activities | -7.00M | -5.72M | -8.51M | -8.92M | -5.61M |
| Issuance of capital stock | 18.55M | 4.38M | 8.51M | 0.00M | - |
| Depreciation | 0.01M | 0.35M | 0.18M | 0.17M | 0.02M |
| Other cashflows from investing activities | -0.54M | - | - | - | - |
| Change to inventory | 0.23M | 0.08M | 0.07M | -0.43M | -0.18M |
| Change to account receivables | -0.33M | 0.10M | -0.07M | 0.00M | -0.07M |
| Other cashflows from financing activities | 16.18M | -0.05M | - | -0.53M | - |
| Capital expenditures | 0.04M | 0.00M | 0.12M | 0.01M | 0.00M |
| Change in working capital | 0.45M | -1.19M | -0.75M | 0.60M | -0.40M |
| Stock based compensation | 0.56M | 0.23M | 0.27M | 0.40M | - |
| Other non cash items | -0.03M | -0.64M | 0.03M | - | 3.26M |
| Free cash flow | -7.04M | -5.72M | -8.63M | -8.93M | -5.61M |
Sector: Healthcare Industry: Biotechnology
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
|---|---|---|---|---|---|---|---|
| VBIO Valion Bio Inc |
-0.05 7.05% |
0.63 | - | - | 1.52 | 0.45 | 0.56 |
| NVO Novo Nordisk A/S |
0.47 1.24% |
38.77 | 41.58 | 31.15 | 2.13 | 32.99 | 2.11 |
| VRTX Vertex Pharmaceuticals Inc |
8.26 1.56% |
537.95 | 30.22 | 24.27 | 10.36 | 6.50 | 9.99 |
| REGN Regeneron Pharmaceuticals Inc |
-0.14 0.02% |
813.12 | 29.07 | 20.12 | 7.57 | 3.82 | 6.95 |
| ARGNF argenx SE |
- -% |
790.15 | 45.77 | 31.25 | 13.84 | 7.12 | 11.38 |
Valion Bio, Inc. operates as a late-stage biopharmaceutical company. Its lead drug candidate is Entolimod, a TLR5 agonist that is in late-stage development to treat acute radiation syndrome. The company's pipeline also comprises Entolimod to treat Neutropenia and lymphocyte exhaustion; and Entolasta, an immunologically optimized variant of Entolimod for chronic applications, such as immunosenescence. In addition, it offers CDMO services. The company was formerly known as Tivic Health Systems, Inc. and changed its name to Valion Bio, Inc. in April 2026. The company was incorporated in 2016 and is based in San Antonio, Texas.
| Name | Title | Year Born |
|---|---|---|
| Ms. Lisa G. Wolf | President, CFO & COO | 1962 |
| Ms. Melinda Lackey | General Counsel & Senior Vice President of Legal Affairs | 1977 |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.
Download a free report with stock ideas and industry insights for general information.
Download Free Report Now →
Basic Materials
-0.49%
Communication Services
+0.04%
Consumer Cyclical
+0.85%
Consumer Defensive
-0.18%
Energy
-0.10%
Financial Services
+0.50%
Financials
-2.64%
Healthcare
+0.41%
Industrials
+0.58%
Real Estate
+0.42%
Technology
-0.57%
Utilities
+0.40%
Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.
Portfolio
Watchlist
Please wait processing your request...